Top ▲
Target not currently curated in GtoImmuPdb
Target id: 2362
Nomenclature: coagulation factor II, thrombin
Systematic Nomenclature: prothrombin
Family: Blood coagulation components, S1: Chymotrypsin
This target is also described as a ligand entry: thrombin; thrombin; thrombin
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 622 | 11p11.2 | F2 | coagulation factor II, thrombin | |
Mouse | - | 618 | 2 50.63 cM | F2 | coagulation factor II | |
Rat | - | 617 | 3q24 | F2 | coagulation factor II, thrombin |
Previous and Unofficial Names |
coagulation factor II | Cf2 | coagulation factor 2 | coagulation factor II (thrombin) | FII | thrombin |
Database Links | |
Specialist databases | |
MEROPS | S01.217 (Hs) |
Other databases | |
Alphafold | P00734 (Hs), P19221 (Mm), P18292 (Rn) |
BRENDA | 3.4.21.5 |
CATH/Gene3D | 4.10.740.10, 4.10.140.10 |
ChEMBL Target | CHEMBL204 (Hs), CHEMBL1075308 (Mm), CHEMBL3078 (Rn) |
DrugBank Target | P00734 (Hs), P00734 (Hs), P00734 (Hs) |
Ensembl Gene | ENSG00000180210 (Hs), ENSMUSG00000027249 (Mm), ENSRNOG00000016325 (Rn) |
Entrez Gene | 2147 (Hs), 14061 (Mm), 29251 (Rn) |
Human Protein Atlas | ENSG00000180210 (Hs) |
KEGG Enzyme | 3.4.21.5 |
KEGG Gene | hsa:2147 (Hs), mmu:14061 (Mm), rno:29251 (Rn) |
OMIM | 176930 (Hs) |
Orphanet | ORPHA121671 (Hs) |
Pharos | P00734 (Hs) |
RefSeq Nucleotide | NM_000506 (Hs), NM_010168 (Mm), NM_022924 (Rn) |
RefSeq Protein | NP_000497 (Hs), NP_034298 (Mm), NP_075213 (Rn) |
SynPHARM | 78498 (in complex with melagatran) |
UniProtKB | P00734 (Hs), P19221 (Mm), P18292 (Rn) |
Wikipedia | F2 (Hs) |
Enzyme Reaction | ||||
|
Download all structure-activity data for this target as a CSV file
Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Immuno Process Associations | ||
|
||
|
||
|
||
|
Clinically-Relevant Mutations and Pathophysiology | ||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
1. AstraZeneca. AZ12971554. Accessed on 12/09/2014. Modified on 12/09/2014. astrazeneca.com, http://openinnovation.astrazeneca.com/what-we-offer/compound/az12971554/
2. Deinum J, Mattsson C, Inghardt T, Elg M. (2009) Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637. Thromb Haemost, 101 (6): 1051-9. [PMID:19492147]
3. Eriksson BI, Wille-Jørgensen P, Kälebo P, Mouret P, Rosencher N, Bösch P, Baur M, Ekman S, Bach D, Lindbratt S et al.. (1997) A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med, 337 (19): 1329-35. [PMID:9358126]
4. Galemmo RA Jr., Fevig JM, Carini DJ, Cacciola J, Wells BL, Hillyer GL, Buriak J Jr., Rossi KA, Stouten PFW, Alexander RS et al.. (1996) (N-acyl-N-alkyl)glycyl borolysine analogs: A new class of potent thrombin inhibitors. Bioorg Med Chem Lett, 6 (24): 2913–2918.
5. Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, Elg M, Mattsson C, Deinum J, Pehrsson S et al.. (1998) Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost, 79 (1): 110-8. [PMID:9459334]
6. Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. (2002) Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem, 45 (9): 1757-66. [PMID:11960487]
7. Imiya M, Matsuo T. (1997) Inhibition of collagen-induced platelet aggregation by argatroban in patients with acute cerebral infarction. Thromb Res, 88 (2): 245-50. [PMID:9361377]
8. Johnson PH, Sze P, Winant RC, Hudson D, Underhill P, Lazar JB, Olsen C, Almquist R. (1991) Structure-function and refolding studies of the thrombin-specific inhibitor hirudin. Haemostasis, 21 Suppl 1: 41-8. [PMID:1894196]
9. Seidel H, Kolde HJ. (2018) Monitoring of Argatroban and Lepirudin: What is the Input of Laboratory Values in "Real Life"?. Clin Appl Thromb Hemost, 24 (2): 287-294. [PMID:28320219]
10. Setyono-Han B, Stürzebecher J, Schmalix WA, Muehlenweg B, Sieuwerts AM, Timmermans M, Magdolen V, Schmitt M, Klijn JG, Foekens JA. (2005) Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb Haemost, 93 (4): 779-86. [PMID:15841327]
11. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F et al.. (2006) Bivalirudin for patients with acute coronary syndromes. N Engl J Med, 355 (21): 2203-16. [PMID:17124018]
12. Warkentin TE, Greinacher A, Craven S, Dewar L, Sheppard JA, Ofosu FA. (2005) Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thromb Haemost, 94 (5): 958-64. [PMID:16363236]
13. Wienen W, Stassen J-M, Priepke H, Ries UJ, Hauel N. (2007) In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thrombosis and Haemostasis, 98 (01): 155-162. DOI: DOI: 10.1160/TH07-03-0183
14. Witting JI, Bourdon P, Brezniak DV, Maraganore JM, Fenton 2nd JW. (1992) Thrombin-specific inhibition by and slow cleavage of hirulog-1. Biochem J, 283 ( Pt 3): 737-43. [PMID:1290488]